BioLineRx (NASDAQ:BLRX – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and target prices for BioLineRx and Mirum Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
Mirum Pharmaceuticals has a consensus price target of $155.56, indicating a potential upside of 67.20%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than BioLineRx.
Valuation and Earnings
This table compares BioLineRx and Mirum Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLineRx | $1.39 million | 4.21 | -$1.17 million | ($1.69) | -0.70 |
| Mirum Pharmaceuticals | $670.78 million | 9.06 | -$23.36 million | ($15.47) | -6.01 |
BioLineRx has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
BioLineRx has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Institutional & Insider Ownership
1.6% of BioLineRx shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares BioLineRx and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLineRx | -502.08% | -34.80% | -18.27% |
| Mirum Pharmaceuticals | -134.75% | -97.25% | -12.59% |
Summary
Mirum Pharmaceuticals beats BioLineRx on 9 of the 15 factors compared between the two stocks.
About BioLineRx
BioLineRx Ltd. is an Israel-based biopharmaceutical company that develops therapies for cancer and other serious diseases. Founded in 2003, the company advances drug candidates through clinical development and works with commercial and development partners. Its lead product, motixafortide, is marketed in the United States as Aphexda. The FDA approved Aphexda, in combination with filgrastim, to mobilize hematopoietic stem cells for collection in adults with multiple myeloma who are preparing for autologous transplantation.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
